| Not Yet Recruiting | Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advance NCT07120451 | Fudan University | Phase 2 |
| Recruiting | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors NCT06997029 | Bristol-Myers Squibb | Phase 1 |
| Not Yet Recruiting | Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to N NCT07059676 | Clinica Universidad de Navarra, Universidad de Navarra | — |
| Active Not Recruiting | Centralization and Oncologic Outcomes in Ovarian Cancer NCT07075939 | Azienda USL Reggio Emilia - IRCCS | — |
| Active Not Recruiting | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases NCT06940921 | Zhang Tao | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treat NCT06542549 | Anhui Provincial Hospital | Phase 3 |
| Recruiting | A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha NCT06547840 | Epsilogen Ltd | Phase 1 |
| Not Yet Recruiting | Plasmodium Immunotherapy for Advanced Ovarian Cancer NCT05924776 | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. | Phase 2 / Phase 3 |
| Not Yet Recruiting | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer NCT05794659 | Aston Sci. Inc. | Phase 2 |
| Unknown | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer NCT06055348 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Can NCT05775549 | AstraZeneca | — |
| Active Not Recruiting | SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS NCT04862325 | Hospital Clinic of Barcelona | N/A |
| Unknown | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer NCT04556539 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Phase 2 |
| Active Not Recruiting | The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer NCT04065009 | Karolinska Institutet | Phase 3 |
| Completed | Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer NCT04360629 | Jun Zhang | N/A |
| Completed | Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Can NCT04135521 | Far Eastern Memorial Hospital | — |
| Recruiting | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer NCT03878849 | Allarity Therapeutics | Phase 2 |
| Active Not Recruiting | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bev NCT03737643 | AstraZeneca | Phase 3 |
| Unknown | Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer NCT03611179 | Nada Hassan Salah | Phase 2 |
| Completed | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin NCT03161132 | Grupo Español de Investigación en Cáncer de Ovario | Phase 2 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 An NCT03292172 | Hoffmann-La Roche | Phase 1 |
| Completed | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial NCT03158935 | University Health Network, Toronto | Phase 1 |
| Completed | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mu NCT01989546 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Ba NCT01844986 | AstraZeneca | Phase 3 |
| Completed | Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer NCT01462149 | Asan Medical Center | Phase 2 |
| Completed | Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors NCT01290471 | Daiichi Sankyo | Phase 1 |
| Completed | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclita NCT00516724 | AstraZeneca | Phase 1 |